pneumonia

Clinical-stage pharmaceutical firm Cempra has obtained fast track designation from the US Food and Drug Administration (FDA) for solithromycin intravenous (IV) and capsules to treat community acquired bacterial pneumonia (CABP).

Currently, the company is carrying out phase three trials for solithromycin to treat CABP and plans to submit a new drug application (NDA) in 2016.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The firm also designed a phase three trial with solithromycin in uncomplicated gonorrhoea, which is expected to complete patient enrolment by the end of this year.

Additional clinical trials with solithromycin include a phase II trial in chronic obstructive pulmonary disease (COPD), a phase two trial in nonalcoholic steatohepatitis (NASH) and a Phase 1b trial in paediatric patients.

Cempra president and CEO Prabhavathi Fernandes said: "We are pleased that the FDA has granted Fast Track status for solithromycin IV and capsules in the treatment of CABP.

See Also:

"We look forward to working with the FDA to streamline the development and review of this promising drug and we currently remain on track to release top line data from our phase three solithromycin IV clinical study"

"We look forward to working with the FDA to streamline the development and review of this promising drug and we currently remain on track to release top line data from our phase three solithromycin IV clinical study conducted in patients with CABP by the end of this year."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earlier, solithromycin IV and capsules received FDA approval to treat CABP and solithromycin capsules to treat gonorrhoea as a qualified infectious disease product (QIDP).

Cempra collaborated with Toyama Chemical, a subsidiary of Fujifilm Holding, for certain exclusive rights in Japan.

The firm’s second product includes Taksta (CEM-102), which is being developed for chronic oral treatment of refractory infections in bones and joints.

Image: A very prominent pneumonia of the middle lobe of the right lung. Photo: courtesy of James Heilman, MD.